ACM
VTGN icon

ACT Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

ACT Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,333
Closed -$315K – 135
2021
Q2 		$315K Buy
+3,333
New +$247K 0.16% 76

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ACT Capital Management's VTGN Position: Q3 2021 in Review

ACT Capital Management sold out of VistaGen Therapeutics (VTGN) in Q3 2021, closing a stake of 3,333 shares — an estimated $315K sold.

ACT Capital Management first reported a position in VTGN in Q2 2021 and held it in 1 quarter. The position peaked at $315K in Q2 2021. 104 funds tracked by Wall St. Rank hold VTGN as of Q3 2021.

  • ACT Capital Management reported no remaining VistaGen Therapeutics position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 3,333 VistaGen Therapeutics shares in Q3 2021, an estimated $315K.
  • ACT Capital Management first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's VistaGen Therapeutics position peaked at $315K in Q2 2021.
  • 104 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.